Neuromidin in mixed vascular and Alzheimer’s dementia

Authors

Damulin, I. V., Stepkina, D. A., Lokshina, A. B.

Journal

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 111, No.: 2, Pages.: 40-43

Year of Publication

2011

Abstract

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group. The worsening was observed in 40% of patients of the comparison group. The positive effect of the drug on spatial and neurodynamic functions was revealed. No serious side-effects of the treatment were found.;

Keywords

adverse effects, aged, aged, 80 and over, alzheimer disease, aminoquinolines, and, cholinesterase inhibitors, dementia vascular, drug therapy, female, functions, humans, ipidacrinum, male, middle aged, neurodynamic, neuromidin, neyromidin, or, spatial, therapeutic use, treatment outcome

Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes

Other

Type of Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime